EGFR and non-small cell lung carcinoma: Three oral EGFR-TKIs, namely gefitinib (Iressa), erlotinib (Tarceva), and afatinib (Giotrif), have recently been approved for first-line use in advanced patients with NSCLC harboring EGFR mutations.